Pharmaxis Ltd's Aspirations Amidst Uncertainties
Pharmaxis Ltd Advances Clinical Trials, Boosts Savings
Pharmaxis Ltd Announces Major Shareholder Changes
Syntara Receives AU$5.2 Million R&D Tax Rebate
Syntara (ASX:PXS) received a research and development tax incentive worth AU$5.2 million for fiscal 2023. "The R&D tax incentive is a significant source of nondilutive funding for the company's clinic
Pharmaxis Doses First Patient in Phase Two Sleep Trial
Pharmaxis (ASX:PXS) dosed the first patient for its phase two trial investigating the use of the medicinal candidate PXS-4728 in individuals afflicted with Rapid Eye Movement Sleep Behavior Disorder w
Pharmaxis Sells Mannitol Business; Shares Fall 3%
Pharmaxis (ASX:PXS) completed the sale of its mannitol respiratory business unit to pharmaceutical manufacturing specialist Arna Pharma, Arna Pharma will reimburse the company for majority of the resi
Pharmaxis Target Price Raised 31% to A$0.17/Share by Morgans>PXS.AU
Pharmaxis Target Price Raised 31% to A$0.17/Share by Morgans>PXS.AU
Pharmaxis to Change Name Amid Restructure, Appoints Chair
Pharmaxis (ASX:PXS) is planning to change its name to Syntara as it undertakes a company restructuring to focus on the treatment of blood-related cancers. The company is selling its mannitol respirato
Pharmaxis to Be Renamed Syntara and Will Primarily Focus on Clinical Development
Pharmaxis to Be Renamed Syntara and Will Primarily Focus on Clinical Development
Pharmaxis Chair Malcolm McComas Retires
Pharmaxis Chair Malcolm McComas Retires
Pharmaxis to Sell Mannitol Respiratory Business to Arna Pharma
Pharmaxis to Sell Mannitol Respiratory Business to Arna Pharma
Pharmaxis Plans 'Major' Restructuring
Pharmaxis Plans 'Major' Restructuring
Australian Bourse Halts Trading in Pharmaxis' Securities
The Australian stock exchange has placed Pharmaxis' (ASX:PXS) securities on trading halt pending an announcement regarding an update about a company restructuring effective today. The pharmaceutical c
Pharmaxis Target Price Cut 46% to A$0.13/Share by Morgans>PXS.AU
Pharmaxis Target Price Cut 46% to A$0.13/Share by Morgans>PXS.AU
Pharmaxis Secures $4 Million R&D Loan
Pharmaxis (ASX:PXS) secured AU$4.4 million in a short-term loan facility with lender Paddington Street Finance, according to a Tuesday report. The loan was made against the drug development firm's exp
Pharmaxis Logs Positive Results in Cancer Trial
Clinical stage drug developer Pharmaxis (ASX:PXS) said 60% of all patients treated under the firm's Myelofibrosis Phase 2 Cancer Trial showed improvement in fibrosis. Final results from the cohort of
Pharmaxis (ASX:PXS) Releases "Excellent" Final Set of Interim Data From Phase Two Cancer Trial
Proactive News Headlines Including St George Mining, European Lithium, Infinity Lithium Corporation and Pharmaxis Ltd
Pharmaxis Ltd (ASX:PXS) Insider Gary Phillips Acquires 1,640,450 Shares
Pharmaxis Ltd (ASX:PXS – Get Rating) insider Gary Phillips acquired 1,640,450 shares of the firm's stock in a transaction dated Tuesday, November 1st. The stock was bought at an average cost of A$0.0
No Data